Interim Report January - March 2015

STRONG GROWTH AND 6 XPS™ DELIVERED
FIRST QUARTER 2015 (JAN – MAR)

• Net sales in the quarter amounted to SEK 31.8 (18.3) million, corresponding to
an increase of 74 percent.
• Operating income before depreciation and amortization (EBITDA) excluding one
-time expenses amounted to SEK 4.5 (3.9) million, corresponding to an EBITDA
margin of 14 percent. One-time expenses of SEK 1.7 (0.8) million related to the
dispute regarding three Vivoline patents/patent applications have been charged
against the quarter. Operating income before depreciation and amortization
(EBITDA) amounted to SEK 2.8 (3.1) million, corresponding to an EBITDA margin of
9 percent.
• Net income amounted to SEK -1.0 (1.8) million, resulting in earnings per share
of SEK -0.05 (0.09), affected by amortization and depreciation of 2.8 million.
• Cash flow from operating activities was SEK -5.9 (-3.3) million due to
increased trade receivables effecting cash flow by -8.3 SEK million.
• Net sales of non-Durable goods* in the quarter amounted to SEK 25.1 (18.3)
million, corresponding to an increase of 38 percent in SEK. Sales of non-Durable
goods increased by 18 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 30 (24) percent of the total sales of non-Durable
goods.
• During the quarter 6 XPS™ were delivered, of which 2 to Europe and 4 to the
US. At the end of the quarter 19 clinics have access to the XPS™, of which 16
are located in the US.
• XVIVO Perfusion and Vivoline have reached an agreement whereby, amongst other
things, XVIVO Perfusion withdraws its claim at Lund District Court and
compensates Vivoline for trial costs. Through this agreement, the parties'
differences in regard to the dispute have been definitively settled.
• XVIVO Perfusion has received TGA approval of XPS™ (Xvivo Perfusion System).
This enables sales of XPS™ in Australia.
• The United States Patent and Trademark Office (USPTO) has approved a third
patent in the “Preservation and evaluation solution” family.  This means that
STEEN Solution™ has broader patent protection in the USA.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on
Wednesday, April 22, 2015. Telephone: +44 (0) 1452 555566, enter code 15343045.

April 22, 2015
Gothenburg

XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

* Durable goods are sales revenues from the XPS™.
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on April 22, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com